No Data
No Data
Viking Therapeutics Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates Coverage On Viking Therapeutics With Overweight Rating, Announces Price Target of $104
Leadership in Action: Max Roix Promoted to Advisor for Viking M&A's Florida Division
Why Viking Therapeutics Stock Popped Today
Truist Securities Reiterates Buy on Viking Therapeutics, Lowers Price Target to $75
Viking Therapeutics Participates in a Conference Call With Maxim Group